...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: from IR "Hepalink does not own Zenith shares."

Thursday 27th at 1pm. Same place its been for the last number of years we were able to attend at Mount Royal University.

tada 

Share
New Message
Please login to post a reply